Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12532102 | 0.80 | MCHR1 (0.47) | DRD2DRD3MCHR1HTR2C | |
| SCHEMBL12531980 | 0.79 | MCHR1 (0.64) | MCHR1 | |
| SCHEMBL12531976 | 0.79 | MCHR1 (0.54) | DRD2DRD3MCHR1HTR2C | |
| SCHEMBL12531977 | 0.76 | LTA4H (0.52) | MCHR1HTR2CPTGS2 | |
| SCHEMBL12531999 | 0.75 | HTR2C (0.51) | DRD3MCHR1HTR2C | |
| SCHEMBL12531994 | 0.73 | HTR2C (0.65) | DRD3MCHR1HTR2C | |
| SCHEMBL12531954 | 0.73 | MCHR1 (0.62) | TMEM97SIGMAR1DRD3MCHR1HTR2C | |
| SCHEMBL4899236 | 0.73 | HTR2C (0.56) | MCHR1HTR2C | |
| SCHEMBL12532001 | 0.73 | MCHR1 (0.57) | TMEM97SIGMAR1DRD3MCHR1HTR2C | |
| SCHEMBL14458662 | 0.72 | MCHR1 (0.38) | SIGMAR1DRD2DRD3MCHR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956049-B2 | Melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-07 | — | — | US | disclosed |
| US-7956049-B2 | Melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090221548-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-03 | — | — | US | disclosed |
| US-20090221548-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-03 | — | — | US | disclosed |
| US-20070185097-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070185097-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221548-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | TMEM97 337/4885SIGMAR1 76/4885DRD2 114/4885 |
| US-20070185097-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | TMEM97 337/4885SIGMAR1 76/4885DRD2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.